Arcellx, Inc. (ACLX)
$
64.87
-1.40 (-2.16%)
Key metrics
Financial statements
Free cash flow per share
-3.5551
Market cap
3.6 Billion
Price to sales ratio
100.1080
Debt to equity
0.1175
Current ratio
3.9874
Income quality
0.9092
Average inventory
0
ROE
-0.5113
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Arcellx, Inc., a clinical-stage biotechnology company, is focused on developing innovative immunotherapies for patients battling cancer and other serious illnesses. The company reported an income before tax of -$105,279,000.00 showcasing its pre-tax profitability, which reflects its effective business strategies and investment in advanced therapies. Additionally, the company reported depreciation and amortization expenses of $5,188,000.00 indicating the wear and tear of its assets as it scales its development efforts. To support its operations, Arcellx reported selling, general, and administrative expenses of $88,414,000.00 which highlight its operational overhead costs associated with running a clinical-stage organization. The net total of other income and expenses is $32,292,000.00 reflecting non-core financial activities that influence the overall financial health of the company. The operating income ratio is -1.27 indicating the company's operational profitability margin, further solidifying its position in the competitive biotechnology landscape. As Arcellx continues its clinical trials and advances its product candidates, including CART-ddBCMA for relapsed or refractory multiple myeloma, it demonstrates its commitment to addressing unmet medical needs. In the financial market, the stock is reasonably priced at $77.86 appealing to a broad range of investors who seek opportunities in the biotechnology field. The stock has an average trading volume of 928,739.00 indicating moderate liquidity that reflects investor interest and active market participation. With a mid-range market capitalization of $3,593,677,861.00 the company is a steady performer, ranked among notable players in the clinical-stage biotechnology industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its pioneering therapies and research initiatives. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it works towards providing solutions for challenging health issues and enhancing the quality of life for patients.
Is Arcellx, Inc. (ACLX) a good investment?
Investing in Arcellx, Inc. (ACLX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Arcellx, Inc. (ACLX)'s stock forecast?
Analysts predict Arcellx, Inc. stock to fluctuate between $47.86 (low) and $94.07 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Arcellx, Inc.'s market capitalization?
As of 2026-01-12, Arcellx, Inc.'s market cap is $3,593,677,861, based on 55,398,148 outstanding shares.
How does Arcellx, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Arcellx, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Arcellx, Inc. (ACLX) stock?
To buy Arcellx, Inc. (ACLX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACLX. Place an order (Market, Limit, etc.).
What is the best time to invest in Arcellx, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Arcellx, Inc. perform in the last earnings report?
Revenue: $107,936,000 | EPS: -$2 | Growth: 36.05%.
Where can I find Arcellx, Inc.'s investor relations reports?
Visit https://arcellx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Arcellx, Inc.?
You can explore historical data from here
What is the all-time high and low for Arcellx, Inc. stock?
All-time high: $107.37 (2024-11-12) | All-time low: $6.04 (2022-05-17).
What are the key trends affecting Arcellx, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, and scalable manufacturing. ACLX's $576 million cash runway extends into 2028, mitigating dilution risk and supporting its transition to commercialization post-2026 launch. Anito-cel's 96% ORR, 74% CR/sCR, and clean safety profile differentiate it from competitors, especially against Carvykti's neurotoxicity concerns.
benzinga.com
Arcellx Inc. (NASDAQ: ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).
seekingalpha.com
Arcellx, Inc. (ACLX) Discusses Phase 2 iMMagine-1 Study Results and Multiple Myeloma Treatment Advances Transcript
businesswire.com
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o.
seekingalpha.com
Arcellx, Inc. (NASDAQ:ACLX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants Rami Elghandour - Chairman of the Board, CEO & President Christopher Heery - Chief Medical Officer Michelle Gilson - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Good afternoon, everyone. Welcome to the session of the Morgan Salary Global Healthcare Conference.
seekingalpha.com
Arcellx, Inc. is advancing its lead CAR-T therapy, anito-cel, for relapsed/refractory multiple myeloma, with the pivotal phase 3 iMMagine-3 trial underway. Recent positive phase 2 iMMagine-1 data support the potential of anito-cel, especially in 2nd-line+ multiple myeloma patients who failed prior therapies. The FDA has allowed a dual primary endpoint—progression-free survival and MRD-negativity—in the ongoing phase 3 iMMagine-3 study, enhancing regulatory prospects.
businesswire.com
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the EHA2025 Congress in Milan.
seekingalpha.com
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts.
globenewswire.com
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University.
seekingalpha.com
Arcellx's innovative cell therapy platform shows promising potential in treating multiple myeloma, a significant unmet medical need. Strong clinical trial results and strategic partnerships bolster confidence in Arcellx's growth trajectory and market position. Clarity is needed around mechanistic differentiation on D-Domain safety results before fully buying into the story.
See all news
